Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five-year project funded by the European Commission's Innovative Medicines Initiative (IMI) 2 programme to evaluate different ways of assessing clinical patient preferences.
The Joint Action on Rare Cancers (JARC) aims to integrate and maximize efforts of the European Commission and EU Member States to advance quality of care and research on rare cancers. The Joint Action and the European Reference Networks are crucial game changers for rare cancer patients in Europe.
ECPC is establishing a Bladder Cancer Working Group to guarantee that bladder cancer patients and patient organisations will be able to contribute to our bladder cancer activities. Click here and join our Bladder Cancer Working Group!
ECPC's Nutrition Booklet launched
The Document addresses common questions patents might have about diet, nutrition, and physical activity during treatment and provides general information regarding nutrition and cancer.